| Dr Patrick M D'souza, MD | |
|
339 Consort Dr, Ballwin, MO 63011-4439 | |
| (636) 386-9224 | |
| (636) 386-7679 |
| Full Name | Dr Patrick M D'souza |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 18 Years |
| Location | 339 Consort Dr, Ballwin, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427260165 | NPI | - | NPPES |
| 1427260165 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 2010017700 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital St Louis | Saint louis, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Anesthesiology Associates Inc | 6204720667 | 175 |
News Archive
TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, today announces the signature of a strategic R&D collaboration agreement with the University of British Columbia (UBC) in Vancouver, Canada, a leading global center for multidisciplinary research and teaching.
Researchers at the Yerkes National Primate Research Center of Emory University are the first to demonstrate a combination of drug therapies targeting the region of the brain that controls drug abuse and addiction significantly reduces cocaine use in nonhuman primates.
Researchers at the National Institute of Allergy and Infectious Diseases and Moderna Inc., have described the potent neutralizing effects of a candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is currently being tested in a phase II trial.
A new analysis from the American Migraine Prevalence and Prevention Study, one of the largest longitudinal studies of headache, indicates that employees suffering from Chronic Migraine (CM) experience increased lost productive time (LPT) in the workplace.
› Verified 5 days ago
| Entity Name | Western Anesthesiology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275646754 PECOS PAC ID: 6204720667 Enrollment ID: O20040226000438 |
News Archive
TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, today announces the signature of a strategic R&D collaboration agreement with the University of British Columbia (UBC) in Vancouver, Canada, a leading global center for multidisciplinary research and teaching.
Researchers at the Yerkes National Primate Research Center of Emory University are the first to demonstrate a combination of drug therapies targeting the region of the brain that controls drug abuse and addiction significantly reduces cocaine use in nonhuman primates.
Researchers at the National Institute of Allergy and Infectious Diseases and Moderna Inc., have described the potent neutralizing effects of a candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is currently being tested in a phase II trial.
A new analysis from the American Migraine Prevalence and Prevention Study, one of the largest longitudinal studies of headache, indicates that employees suffering from Chronic Migraine (CM) experience increased lost productive time (LPT) in the workplace.
› Verified 5 days ago
| Entity Name | Ssm Health Care Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306589544 PECOS PAC ID: 0143608372 Enrollment ID: O20220531002655 |
News Archive
TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, today announces the signature of a strategic R&D collaboration agreement with the University of British Columbia (UBC) in Vancouver, Canada, a leading global center for multidisciplinary research and teaching.
Researchers at the Yerkes National Primate Research Center of Emory University are the first to demonstrate a combination of drug therapies targeting the region of the brain that controls drug abuse and addiction significantly reduces cocaine use in nonhuman primates.
Researchers at the National Institute of Allergy and Infectious Diseases and Moderna Inc., have described the potent neutralizing effects of a candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is currently being tested in a phase II trial.
A new analysis from the American Migraine Prevalence and Prevention Study, one of the largest longitudinal studies of headache, indicates that employees suffering from Chronic Migraine (CM) experience increased lost productive time (LPT) in the workplace.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Patrick M D'souza, MD 339 Consort Dr, Ballwin, MO 63011-4439 Ph: (636) 386-9224 | Dr Patrick M D'souza, MD 339 Consort Dr, Ballwin, MO 63011-4439 Ph: (636) 386-9224 |
News Archive
TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, today announces the signature of a strategic R&D collaboration agreement with the University of British Columbia (UBC) in Vancouver, Canada, a leading global center for multidisciplinary research and teaching.
Researchers at the Yerkes National Primate Research Center of Emory University are the first to demonstrate a combination of drug therapies targeting the region of the brain that controls drug abuse and addiction significantly reduces cocaine use in nonhuman primates.
Researchers at the National Institute of Allergy and Infectious Diseases and Moderna Inc., have described the potent neutralizing effects of a candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is currently being tested in a phase II trial.
A new analysis from the American Migraine Prevalence and Prevention Study, one of the largest longitudinal studies of headache, indicates that employees suffering from Chronic Migraine (CM) experience increased lost productive time (LPT) in the workplace.
› Verified 5 days ago
Tammara S Goldschmidt, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 339 Consort Dr, Ballwin, MO 63011 Phone: 636-386-9224 Fax: 636-386-7679 | |
Daniel Peter Alyea, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 339 Consort Dr, Ballwin, MO 63011 Phone: 636-386-9224 | |
Dr. Jeffrey Alexander, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 351 Consort Dr, Ballwin, MO 63011 Phone: 636-200-4242 Fax: 636-200-4243 | |
Dr. Matthew H Bigham, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 339 Consort Dr, Ballwin, MO 63011 Phone: 636-386-9224 Fax: 636-386-7679 | |
Matthew Casey, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 339 Consort Dr, Ballwin, MO 63011 Phone: 636-386-9224 Fax: 636-386-7679 | |
Elizabeth Cohen, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 339 Consort Dr, Ballwin, MO 63011 Phone: 636-386-9224 |